RTHM vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 38)
RTHM logo

RTHM

EmergingHealthcare

Remote Patient Monitoring

RTHM is a remote patient monitoring platform that uses wearable devices and AI to track chronic disease patients between clinical visits, enabling proactive care intervention. HQ: San Francisco.

AI VisibilityBeta
Overall Score
D38
Category Rank
#453 of 596
AI Consensus
88%
Trend
stable
Per Platform
ChatGPT
38
Perplexity
38
Gemini
42

About

RTHM is a remote patient monitoring (RPM) company providing technology and clinical services to help healthcare providers track patients with chronic conditions between office visits. The platform uses FDA-cleared wearable devices to continuously or periodically measure vital signs, symptoms, and disease-specific biomarkers, transmitting data to a clinical monitoring center where RTHM's care team reviews alerts and communicates with patients experiencing concerning trends before they escalate to emergency care.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

38
Overall Score
81
#453
Category Rank
#17
88
AI Consensus
71
stable
Trend
stable
38
ChatGPT
80
38
Perplexity
75
42
Gemini
77
37
Claude
86
38
Grok
85

Key Details

Category
Remote Patient Monitoring
General
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only RTHM
Remote Patient Monitoring

Integrations

Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.